• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Ekso Bionics Holdings Inc.

    4/18/25 4:25:35 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials
    Get the next $EKSO alert in real time by email
    11-K 1 ekso20241231_11k.htm FORM 11-K ekso20241231_11k.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 11-K

     

    ☑ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the fiscal year ended December 31, 2024

     

    OR

     

    ☐TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from ____________ to _____________.

     

    Commission File Number: 001-37854

     

    EKSO BIONICS 401(K) PLAN

    (Full title of the plan)

     

    EKSO BIONICS HOLDINGS, INC.

    (Name of issuer of the securities held pursuant to the Plan)

     

    101 Glacier Point, Suite A

    San Rafael, California 94901

    (Address of principal executive office)

     

    REQUIRED INFORMATION

     

    The financial statements of the Ekso Bionics 401(k) Plan (the “Plan”) for the fiscal year ended December 31, 2024 are attached as a supplement to, and included in, this Annual Report on Form 11-K. The Plan is subject to the requirements of the Employee Retirement Income Security Act of 1974 (“ERISA”) and such financial statements have been prepared in accordance with the financial reporting requirements of ERISA. Under ERISA, such financial statements are not required to be examined by an independent accountant, without reliance on the “limited scope exemption” contained in Section 103(a)(3)(C) of ERISA.

    Financial Statements Supplement

     

     

     

     

    SCHEDULE I

     

    Financial Information—Small Plan

     

    OMB No. 1210-0110

             

    (Form 5500)

     

    Department of the Treasury

     

    Internal Revenue Service

     

    Department of Labor

     

    This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA), and section 6058(a) of the Internal Revenue Code (the Code).

     

    2024

             

    Employee Benefits

    Security Administration

     

    Pension Benefit

    Guaranty Corporation

     

    ►File as an attachment to Form 5500.

     

    This Form is Open to

    Public Inspection

     

    For calendar plan year 2024 or fiscal plan year beginning 01/01/2024 and ending 12/31/2024

     

    A

     

    Name of plan

     

    B

     

    Three-digit plan number (PN) ►

    001

    Ekso Bionics 401(k) Plan

               
                 

    C

     

    Plan sponsor’s name as shown on line 2a of Form 5500

     

    D

     

    Employer Identification Number (EIN)

                 

    Ekso Bionics, Inc.

           

    87-0741846

     

    Complete Schedule I if the plan covered fewer than 100 participants as of the beginning of the plan year. You may also complete Schedule I if you are filing as a small plan under the 80-120 participant rule (see instructions). Complete Schedule H if reporting as a large plan or DFE.

     

     

     

     

    Part I Small Plan Financial Information

     

    Report below the current value of assets and liabilities, income, expenses, transfers and changes in net assets during the plan year. Combine the value of plan assets held in more than one trust. Do not enter the value of the portion of an insurance contract that guarantees during this plan year to pay a specific dollar benefit at a future date. Include all income and expenses of the plan including any trust(s) or separately maintained fund(s) and any payments/receipts to/from insurance carriers. Round off amounts to the nearest dollar.

     

    1

     

    Plan Assets and Liabilities:

     

    (a)

    Beginning
    of Year

     

    (b)

    End of
    Year

       

    a

     

    Total plan assets

    1a

    5,804,695  

    6,443,607

       

    b

     

    Total plan liabilities

    1b

    -

     

    -

       

    c

     

    Net plan assets (subtract line 1b from line 1a)

    1c

    5,804,695  

    6,443,607

     

    2

     

    Income, Expenses, and Transfers for this Plan Year:

     

    (a) Amount

     

    (b) Total

       

    a

     

    Contributions received or receivable:

           
           

    (1)   Employers

    2a(1)

    326,550

       
           

    (2)   Participants

    2a(2)

    774,321

       
           

    (3)   Others (including rollovers)

    2a(3)

    202,584

       
       

    b

     

    Noncash contributions

    2b

    -

       
       

    c

     

    Other income

    2c

    228,681

       
       

    d

     

    Total income (add lines 2a(1), 2a(2), 2a(3), 2b, and 2c)

    2d

       

    1,532,136

       

    e

     

    Benefits paid (including direct rollovers)

    2e

    844,834

       
       

    f

     

    Corrective distributions (see instructions)

    2f

    -

       
       

    g

     

    Certain deemed distributions of participant loans (see instructions)

    2g

    -

       
       

    h

     

    Administrative service providers (salaries, fees, and commissions)

    2h

    48,390

       
       

    i

     

    Other expenses

    2i

    -

       
       

    j

     

    Total expenses (add lines 2e, 2f, 2g, 2h, and 2i)

    2j

       

    893,224

       

    k

     

    Net income (loss) (subtract line 2j from line 2d)

    2k

       

    638,912

       

    l

     

    Transfers to (from) the plan (see instructions)

    2l

       

    -

     

    3

    Specific Assets: If the plan held assets at any time during the plan year in any of the following categories, check “Yes” and enter the current value of any assets remaining in the plan as of the end of the plan year. Allocate the value of the plan’s interest in a commingled trust containing the assets of more than one plan on a line-by-line basis unless the trust meets one of the specific exceptions described in the instructions.

     

               

    Yes

    No

    Amount

       

    a

     

    Partnership/joint venture interests

    3a

     

    X

     
       

    b

     

    Employer real property

    3b

     

    X

     
       

    c

     

    Real estate (other than employer real property)

    3c

     

    X

     
       

    d

     

    Employer securities

    3d

    X

     

    183,788

       

    e

     

    Participant loans

    3e

    X

     

    36,050

       

    f

     

    Loans (other than to participants)

    3f

     

    X

     
       

    g

     

    Tangible personal property

    3g

     

    X

     

     

     

     

     

    For Paperwork Reduction Act Notice, see the Instructions for Form 5500.

    Schedule I (Form 5500) 2023

     

         

    v. 230728

    Schedule I (Form 5500) 2023

     

    Page 2 - ☐

     

     

    Part II Compliance Questions

     

     

    4 During the plan year:   Yes No Amount
       

    a

     

    Was there a failure to transmit to the plan any participant contributions within the time period described in 29 CFR 2510.3-102? Continue to answer “Yes” for any prior year failures until fully corrected. (See instructions and DOL’s Voluntary Fiduciary Correction Program.)

    4a

     

    X

     
       

    b

     

    Were any loans by the plan or fixed income obligations due the plan in default as of the close of plan year or classified during the year as uncollectible? Disregard participant loans secured by the participant’s account balance.

    4b

     

    X

     
       

    c

     

    Were any leases to which the plan was a party in default or classified during the year as uncollectible?

    4c

     

    X

     
       

    d

     

    Were there any nonexempt transactions with any party-in-interest? (Do not include transactions reported on line 4a.)

    4d

     

    X

     
       

    e

     

    Was the plan covered by a fidelity bond?

    4e

    X

     

    1,000,000

       

    f

     

    Did the plan have a loss, whether or not reimbursed by the plan’s fidelity bond, that was caused by fraud or dishonesty?

    4f

     

    X

     
       

    g

     

    Did the plan hold any assets whose current value was neither readily determinable on an established market nor set by an independent third party appraiser?

    4g

     

    X

     
       

    h

     

    Did the plan receive any noncash contributions whose value was neither readily determinable on an established market nor set by an independent third party appraiser?

    4h

     

    X

     
       

    i

     

    Did the plan at any time hold 20% or more of its assets in any single security, debt, mortgage, parcel of real estate, or partnership/joint venture interest?

    4i

    X

     

    5,779,870
       

    j

     

    Were all the plan assets either distributed to participants or beneficiaries, transferred to another plan, or brought under the control of the PBGC?

    4j

     

    X

     
       

    k

     

    Are you claiming a waiver of the annual examination and report of an independent qualified public accountant (IQPA) under 29 CFR 2520.104-46? If “No,” attach an IQPA’s report or 2520.104-50 statement. (See instructions on waiver eligibility and conditions.)

    4k

    X

     

     
       

    l

     

    Has the plan failed to provide any benefit when due under the plan?

    4l

     

    X

     
       

    m

     

    If this is an individual account plan, was there a blackout period? (See instructions and 29 CFR 2520.101-3.)

    4m

    X

     

     
       

    n

     

    If 4m was answered “Yes,” check the “Yes” box if you either provided the required notice or one of the exceptions to providing the notice applied under 29 CFR 2520.101-3.

    4n

    X

     

     

     

     

     

     

    5a

     

    Has a resolution to terminate the plan been adopted during the plan year or any prior plan year? If “Yes,” enter the amount of any plan assets that reverted to the employer this year.

     

    ☐ Yes ☒ No

     
       

    If “Yes”, enter the amount of any plan assets that reverted to the employer this year.

     

    5b

     

    If, during this plan year, any assets or liabilities were transferred from this plan to another plan(s), identify the plan(s) to which assets or liabilities were transferred. (See instructions.)

     

     

    5b(1) Name of plan(s)

     

    5b(2)
    EIN(s)

     

    5b(3)
    PN(s)

                         

    5c

     

    If the plan is a defined benefit plan, is it covered under the PBGC insurance program (See ERISA section 4021.)? ☐ Yes ☐ No ☐ Not determined.

     
           
       

    If “Yes” is checked, enter the My PAA confirmation number from the PBGC premium filing for this plan year. (See instructions.)

     

     

     

     

     

    SIGNATURES

     

    The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Name of Plan: Ekso Bionics 401(k) Plan

     

           

     

    By: 

    Ekso Bionics, Inc., its Plan Administrator

     

     

     

     

     

    Date: April 18, 2025

    By:

    /s/ Jerome Wong

     

     

     

    Name:

    Jerome Wong

     

             

     

     

    Title:

    Chief Financial Officer

     

     

     
    Get the next $EKSO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EKSO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EKSO
    Financials

    Live finance-specific insights

    See more
    • Ekso Bionics Reports First Quarter 2025 Financial Results

      SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

      5/5/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow

      SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.

      4/28/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results

      SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. Recent Highlights and Accomplishments Record Q4-2024 revenue of $5.1 millionQ4-2024 gross margin increased 400 basis points year-over-year to 53%Subsequent to year-end, Company named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology (CRT) industry "We are pleased to close out 2024 with recor

      3/3/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lathan Corinna bought $15,477 worth of shares (13,733 units at $1.13), increasing direct ownership by 10% to 147,990 units (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/14/24 6:41:52 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Reports First Quarter 2025 Financial Results

      SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

      5/5/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow

      SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.

      4/28/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ekso Bionics Holdings Inc.

      10-Q - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/5/25 4:08:10 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/5/25 4:06:47 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form 11-K filed by Ekso Bionics Holdings Inc.

      11-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      4/18/25 4:25:35 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Leadership Updates

    Live Leadership Updates

    See more
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

      Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. "We are pleased to strengthen our Board with the addition of Deborah Lafer Scher, a distinguished leader who brings a wealth of healthcare experience and a proven track record of business development expertise," said Scott Davis, President and Chie

      6/17/24 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation

      Broadens Ekso Bionics' product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the acquisition of the Human Motion and Control ("HMC") Business Unit from Parker Hannifin Corporation ("Parker"), a global leader in motion and control technologies. The acquisiti

      12/5/22 8:37:01 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      11/14/24 3:29:01 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Ekso Bionics Holdings Inc. (Amendment)

      SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/11/22 6:17:59 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/12/21 10:16:25 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Wong Jerome was granted 24,248 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:07:04 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Chief Operating Officer Jones Jason C was granted 24,248 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:06:43 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • CEO Davis Scott G. was granted 5,590 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:06:18 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials